Longitudinal analysis of RCC-specific immunity in renal cell carcinoma patients

Longitudinal analysis of RCC-specific immunity in renal cell carcinoma patients - Analysis of RCC-specific immunity in RCC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON45138

Enrollment

600

Registered

2012-11-21

Start date

2012-10-01

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypernephroma kidney cancer

Interventions

At some time points blood and biopsies will be taken.

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Histologically or cytologically proven renal cell carcinoma Measurable metastatic lesion(s), according to RECIST 1.1 criteria Metastatic lesion(s) of which a histological biopsy can safely be obtained Age above 18 years Performance score: WHO 0, 1 or 2 Written informed consent

Exclusion criteria

Exclusion criteria: see inclusion criteria

Design outcomes

Primary

Measure	Time frame
To study the longitudinal effects of treatment (e.g. anti-CTLA4, BRAF inhibition, and other treatments) for advanced stage renal cell carcinoma on tumor material obtained by surgical removal/biopsies and on peripheral blood components. To find predictive markers and/or prognostic markers in biopsied tumor material and peripheral blood To improve current TIL expansion protocols	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)